$STTK

SIEGALL CLAY B purchased $250K of STTK

SIEGALL CLAY B purchased 62,500 shares of Shattuck Labs, Inc. (STTK) at $4.00 ($0.25M total) on 2026-06-09.

Original reporting
SEC EDGAR · SIEGALL CLAY B
Published Jun 11, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STTK
Bullish
medium confidence
Mentioned
$STTK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STTKBullishLow
01

Why it matters

A director’s open-market purchase (no 10b5-1 plan stated) adds incremental bullish sentiment, but it does not change known business fundamentals by itself.

02

Market read

Traders may treat the filing as a small sentiment input, but it is unlikely to be a primary driver versus upcoming company-specific catalysts.

03

What to watch

The article doesn’t disclose why the director bought or whether other insiders/large holders acted; without clinical/regulatory updates, price reaction may be muted.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-11; transaction dated 2026-06-09

Background

This is an SEC Form 4 insider transaction disclosure for Shattuck Labs, Inc. (STTK).

Company-level read

Ticker impact

$STTKBullishMedium confidence
Context

Director SIEGALL CLAY B bought 62,500 shares of Shattuck Labs at $4.00/share via an open-market purchase disclosed on Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional buys or company catalysts.

Evidence & confidence

Form 4 provides a new, primary-source transaction (new information), but insider buys alone rarely create durable repricing without accompanying operational/regulatory/clinical updates.

Market effects

No sector-wide read-across; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax/portfolio rebalancing) and may not signal improved fundamentals, especially without follow-through.

Key entities

  • Shattuck Labs, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • SIEGALL CLAY B

    Director who purchased 62,500 shares on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STTKMed

Strattec Security Corporation Q4 2026 Earnings Call Summary

Strattec Security Corporation reported record annual revenue of $579.4 million for 2026, driven by pricing, cost actions, and operational improvements. The company reorganized its product portfolio and realized $6 million in restructuring savings, expanding gross margin to 16.5%. Strattec anticipates a challenging 2027 with a 2% decline in North American production and targets long-term gross margins of 18% to 20%. The company maintains a debt-free balance sheet with $108.2 million in cash and p

$STTKMed

Shattuck Labs Jumps as Two Analysts Start Bullish Coverage

Shattuck Labs (STTK) rose 4.91% after two analysts initiated coverage with positive ratings. TD Cowen rated it buy, while Raymond James gave a strong buy and $18 price target. Both highlighted SL-325, a drug candidate for inflammatory bowel disease, citing its novel mechanism. The company reported $208.3M in cash and expects funding into 2029. Phase 2b trial for SL-325 is set to start in Q3.

$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

$STTKMed

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A bi